Navigation Links
Mayo Clinic researchers find new treatment for constipation
Date:5/10/2011

ROCHESTER, Minn. - Constipation is definitely not a glamorous topic. In reality, it affects nearly 30 million Americans and costs more than $1 billion annually to evaluate and treat. While not often life threatening, the pain, bloating, discomfort, and straining associated with constipation lead sufferers to focus on one thing - relief. Mayo Clinic researchers recently had success in the clinical trial of a new medication shown to provide relief from constipation in a way that capitalizes on the body's natural processes.

The drug, called A3309, targets bile acid recycling in the body. Bile acids, created in the liver and released into the digestive system, aid in breaking down fats and absorbing them into the body. Bile acids also are natural laxatives that promote bowel movements by softening stool and speeding up how fast stool moves through the colon. During digestion, most bile acids are absorbed back into the blood in the lower small intestines for recycling, letting very little bile acids to leak into the colon to help facilitate bowel movements. A3309 works by inhibiting bile acid absorption in the small intestines, allowing more bile acids to enter the colon to stimulate bowel movements.

"The new medication is a novel approach which allows the delivery to the colon of normal substances produced by the patient's own liver to induce a laxative effect," says Michael Camilleri, M.D., a gastroenterologist and Atherton and Winifred W. Bean Professor at Mayo Clinic and the study's lead author.

In a Phase II, randomized, double-blind, placebo-controlled study, the Mayo Clinic research team tested the effectiveness of A3309 for two weeks in patients with constipation. The study yielded promising results. The drug sped up the movement of stool through the colon. Patients with constipation who took A3309, compared to those who received placebo, reported significantly less straining and softer stool during bowel movements, says researcher Banny Wong, M.D.

The main side effect of A3309 was abdominal discomfort and pain. Dr. Wong says this occurred mainly before a bowel movement, after which the pain and discomfort usually went away.

According to Dr. Wong, the next step in the drug's development will be Phase III studies that will involve more people and a longer treatment duration.

Dr. Wong is sharing the study's findings at the 2011 Digestive Disease Week international conference May 7-10 at McCormick Place in Chicago.


'/>"/>

Contact: Brian Kilen
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Mayo Clinic studies how much practice makes perfect when performing colonoscopies
2. Cedars-Sinais mobile medical clinics receive $500,000 grant from California Community Foundation
3. TGen licenses first drug for patient use in clinical care
4. Mayo Clinic CPR efforts successful on man with no pulse for 96 minutes
5. ENERCA clinical recommendations for sickle cell disease management and prevention in children
6. Mayo Clinic finds new genetic cause of neurodegeneration
7. Mayo Clinic finds robotic surgery effective for removing hard-to-reach throat cancer
8. UofL nursing faculty honored for race track clinic success
9. Tierney named 2011 Clinical and Translational Research Distinguished Investigator
10. New Pill for MS Shows Promise in Clinical Trial
11. Mayo Clinic finds tool to predict disability timeline for progressive MS patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , ... March 27, 2017 , ... ... Conventional sodium testing methods are complicated and require expert user knowledge. In a ... analytical method dedicated to the simplified, yet highly accurate, determination of sodium. , ...
(Date:3/27/2017)... ... March 27, 2017 , ... Golden Triangle ... 8:00am-10:00am on Monday, April 3rd to commemorate the two-year anniversary of the facility. ... area-residents to celebrate two great years while also familiarizing themselves with the facility. ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... Harris Communications, ... of hearing, is bringing its latest products to the Deaf Seniors of America Conference, ... have the opportunity to meet with knowledgeable ASL friendly staff from Harris Communications and ...
(Date:3/25/2017)... ... ... at Swissray is pleased to announce the release of the ELITE DXA, a new ... active scan window, which is more than double that of existing bone densitometers. Historically, ... undergo an accurate total body bone density or body composition study. The ELITE ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... which will spark a conversation on the current obstacles facing infection prevention and ... completely preventable deaths caused by these infections. , The print component of ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... Israel , March 27, 2017 ... oncology and immunology, announced today that AGI-134, an immunotherapy for ... acquisition of Agalimmune Ltd., will be featured at the upcoming ... in Washington, DC to be held ... ...
(Date:3/27/2017)... 2017  BERG, a biopharmaceutical company uncovering ... approach, today announced that the company,s Interrogative ... new data using a cold-induced model to ... Joslin Diabetes Center led the investigation with ... analysis of samples.  The findings were published ...
(Date:3/27/2017)... BOSTON , March 27, 2017 ... pharmaceutical company and Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), ... commercialization of innovative therapies based upon tetracycline chemistry, ... sarecycline for the treatment of moderate to severe ... Sarecycline is a once-daily, oral, narrow spectrum tetracycline-derived ...
Breaking Medicine Technology: